TC-110 / Adaptimmune - LARVOL DELTA

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=6 | Completed | Sponsor: TCR2 Therapeutics | Recruiting ➔ Completed | N=120 ➔ 6 | Trial completion date: Apr 2024 ➔ Feb 2023 | Trial primary completion date: Apr 2022 ➔ Feb 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) - "TCR2 to present an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in the second half of 2021. TCR2 plans to file an IND for TC-510, the first enhanced TRuC-T cell (targeting mesothelin with a PD-1:CD28 switch), in the second half of 2021."

IND • P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) - “Anticipated Milestones: TCR2 to present additional safety, efficacy and translational data from the Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors throughout 2021. TCR2 to present an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in the second half of 2021. TCR2 plans to file an IND for TC-510, the first enhanced TRuC-T cell targeting mesothelin with a PD-1:CD28 switch, in the second half of 2021.”

IND • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - “Anticipated Milestones: TCR2 to present additional safety, efficacy and translational data from the Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors throughout 2021; TCR2 to present an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2021; TCR2 plans to file an IND for TC-510, the first enhanced TRuC-T cell targeting mesothelin with a PD-1:CD28 switch, in 2021.”

IND • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones (GlobeNewswire) - "TC-110...TRuC-T cell targeting CD19-positive adult acute lymphoblastic leukemia and aggressive or indolent non-Hodgkin lymphoma....Initial safety, efficacy and translational data from Phase 1 dose escalation anticipated in 2021"

P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - “TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 4Q20. TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2021. TCR2 anticipates certification of its manufacturing facility in Stevenage, UK, in 4Q20. TCR2 anticipates an IND filing for a third TRuC-T cell program in 2021.”

Clinical • IND • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - "Anticipated Milestones: TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 2H20. TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2H20. TCR2 anticipates certification of its manufacturing facility in Stevenage, UK, in 2H20. TCR2 anticipates an IND filing for a third TRuC-T cell program in 2021."

Clinical • IND • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TCR² Therapeutics hires key business development and regulatory affairs cell therapy experts to support strategic objectives (GlobeNewswire) - "TCR² Therapeutics Inc...announced an expansion of its leadership team to strengthen expertise in business development and regulatory affairs as the Company advances the development of TRuC^®-T cells addressing solid tumors and hematological malignancies....'we advance our two current TRuC-T cell programs in the clinic, TC-210 and TC-110, and file an IND for our third CD70-targeted mono TRuC program.'"

Clinical • IND • Hematological Malignancies • Oncology

TCR² Therapeutics reports first quarter 2020 financial results and provides corporate update (GlobeNewswire) - "Anticipated Milestones: TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in mid-2020. TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2H20. TCR2 anticipates clinical production of TRuC-T cells at its manufacturing facility in Stevenage, UK, in 2H20. TCR2 anticipates a target IND filing for the third mono TRuC-T cell program targeting CD70 in 1H21."

Clinical • IND • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: TCR2 Therapeutics

Clinical • New P1/2 trial

TCR² Therapeutics reports fourth quarter and full year 2019 financial results and provides corporate update (GlobeNewswire) - “TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 2Q20; TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2H20; TCR2 anticipates clinical production of TRuC-T cells at its manufacturing facility in Stevenage, UK, in 2H20; TCR2 anticipates advancing a third mono TRuC-T cell therapy in 2Q20 with a target IND filing in 1H21.”

Clinical • IND • New trial • P1/2 data